Narayan Rajan

546 total citations
21 papers, 422 citations indexed

About

Narayan Rajan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Economics and Econometrics. According to data from OpenAlex, Narayan Rajan has authored 21 papers receiving a total of 422 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 8 papers in Economics and Econometrics. Recurrent topics in Narayan Rajan's work include Health Systems, Economic Evaluations, Quality of Life (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Gastric Cancer Management and Outcomes (6 papers). Narayan Rajan is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Gastric Cancer Management and Outcomes (6 papers). Narayan Rajan collaborates with scholars based in United States, China and Australia. Narayan Rajan's co-authors include Andrew Lloyd, Beenish Nafees, Sarah Dewilde, María Gabriela Lorenzo, Peter Davey, David J. Grainger, M Aristides, Peter Davey, Astra M. Liepa and Gebra Cuyún Carter and has published in prestigious journals such as Journal of Clinical Oncology, BMC Cancer and Journal of Thoracic Oncology.

In The Last Decade

Narayan Rajan

19 papers receiving 407 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Narayan Rajan United States 10 234 228 97 75 48 21 422
Abhishek Kumar United States 12 186 0.8× 202 0.9× 76 0.8× 72 1.0× 13 0.3× 37 405
P. P. A. Razenberg Netherlands 5 210 0.9× 270 1.2× 37 0.4× 54 0.7× 18 0.4× 7 463
Per-Olof Thuresson Switzerland 8 85 0.4× 98 0.4× 97 1.0× 44 0.6× 138 2.9× 22 390
Shanthi Sivendran United States 11 167 0.7× 83 0.4× 41 0.4× 32 0.4× 14 0.3× 28 410
Flavia Ejzykowicz United States 9 173 0.7× 158 0.7× 65 0.7× 50 0.7× 100 2.1× 42 367
Noman Paracha Switzerland 12 132 0.6× 104 0.5× 105 1.1× 43 0.6× 10 0.2× 40 369
Ludovica De Vincentiis Italy 7 202 0.9× 45 0.2× 33 0.3× 52 0.7× 46 1.0× 17 327
Robin Schaffar Switzerland 10 196 0.8× 126 0.6× 34 0.4× 33 0.4× 14 0.3× 19 338
Sophia Y. Chen United States 15 208 0.9× 86 0.4× 48 0.5× 235 3.1× 18 0.4× 37 611
Rebecca M. Prince Canada 9 131 0.6× 102 0.4× 29 0.3× 81 1.1× 24 0.5× 28 292

Countries citing papers authored by Narayan Rajan

Since Specialization
Citations

This map shows the geographic impact of Narayan Rajan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Narayan Rajan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Narayan Rajan more than expected).

Fields of papers citing papers by Narayan Rajan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Narayan Rajan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Narayan Rajan. The network helps show where Narayan Rajan may publish in the future.

Co-authorship network of co-authors of Narayan Rajan

This figure shows the co-authorship network connecting the top 25 collaborators of Narayan Rajan. A scholar is included among the top collaborators of Narayan Rajan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Narayan Rajan. Narayan Rajan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brnabic, Alan, et al.. (2017). P2.03a-022 QOL and Febrile Neutropenia: Japanese Phase 2 Trial of Docetaxel with/out Antiangiogenic Agent in 2nd Line NSCLC. Journal of Thoracic Oncology. 12(1). S901–S901. 1 indexed citations
2.
Rajan, Narayan, Kristina S. Boye, Yoon Ji Lee, et al.. (2016). Utilities for Type 2 Diabetes Treatment-Related Attributes in a South Korean and Taiwanese Population. Value in Health Regional Issues. 9. 67–71. 12 indexed citations
3.
Carter, Gebra Cuyún, Anna Kaltenboeck, Jasmina I. Ivanova, et al.. (2016). Treatment patterns in patients with advanced gastric cancer in Taiwan. Asia-Pacific Journal of Clinical Oncology. 13(3). 185–194. 11 indexed citations
4.
Carter, Gebra Cuyún, Anna Kaltenboeck, Jasmina I. Ivanova, et al.. (2016). Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea. Cancer Research and Treatment. 49(3). 578–587. 21 indexed citations
5.
Nafees, Beenish, Andrew Lloyd, Sarah Dewilde, Narayan Rajan, & María Gabriela Lorenzo. (2016). Health state utilities in non–small cell lung cancer: An international study. Asia-Pacific Journal of Clinical Oncology. 13(5). e195–e203. 218 indexed citations
6.
7.
Carter, Gebra Cuyún, Denise King, Lisa M. Hess, et al.. (2015). Health state utility values associated with advanced gastric, oesophageal, or gastro-oesophageal junction adenocarcinoma: a systematic review. Journal of Medical Economics. 18(11). 954–966. 13 indexed citations
8.
Li, Xiaoling, Yuqin Wang, Yan Wang, et al.. (2015). Supportive Care Costs Associated with Second-Line Chemotherapy in Chinese Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study. Drugs - Real World Outcomes. 2(1). 87–97. 3 indexed citations
9.
Hess, Lisa M., Narayan Rajan, Katherine B. Winfree, et al.. (2015). Cost Analyses in the US and Japan: A Cross-Country Comparative Analysis Applied to the PRONOUNCE Trial in Non-Squamous Non-Small Cell Lung Cancer. Advances in Therapy. 32(12). 1248–1262. 7 indexed citations
10.
11.
12.
Rajan, Narayan, Helen Barraclough, Tarun Puri, & Mauro Orlando. (2014). Cost effectiveness of concurrent gemcitabine and cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in stages IIB–IVA cervical cancer. Gynecologic Oncology Reports. 10. 36–37. 1 indexed citations
13.
14.
Carter, Gebra Cuyún, Anna Kaltenboeck, Jasmina Ivanova, et al.. (2014). Real-world treatment patterns among patients with advanced gastric cancer in South Korea.. Journal of Clinical Oncology. 32(3_suppl). 152–152. 1 indexed citations
15.
Paech, Daniel, Adèle Weston, Nick Pavlakis, et al.. (2010). A Systematic Review of the Interobserver Variability for Histology in the Differentiation between Squamous and Nonsquamous Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(1). 55–63. 26 indexed citations
16.
Davey, Peter, Narayan Rajan, Michael Lees, & M Aristides. (2001). Cost-Effectiveness of Pergolide Compared to Bromocriptine in the Treatment of Parkinson's Disease: A Decision-Analytic Model. Value in Health. 4(4). 308–315. 20 indexed citations
17.
Rajan, Narayan, et al.. (2001). The Heritage Buildings of Bombay. 1 indexed citations
18.
Davey, Peter, et al.. (2000). Patients value the clinical characteristics and convenience of Humalog® mix25™: Results of a willingness to pay study in patients with type 2 diabetes. Diabetes Research and Clinical Practice. 50. 192–193. 1 indexed citations
19.
Davey, Peter, et al.. (1998). Economic Evaluation of Insulin Lispro versus Neutral (Regular) Insulin Therapy Using a Willingness-To-Pay Approach. PharmacoEconomics. 13(3). 347–358. 32 indexed citations
20.
Davey, Peter, et al.. (1997). Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis. Clinical Therapeutics. 19(4). 656–674. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Abhishek Kumar Breakdown of academic impact, for papers by P. P. A. Razenberg Breakdown of academic impact, for papers by Per-Olof Thuresson Breakdown of academic impact, for papers by Shanthi Sivendran Breakdown of academic impact, for papers by Flavia Ejzykowicz Breakdown of academic impact, for papers by Noman Paracha Breakdown of academic impact, for papers by Ludovica De Vincentiis Breakdown of academic impact, for papers by Robin Schaffar Breakdown of academic impact, for papers by Sophia Y. Chen Breakdown of academic impact, for papers by Rebecca M. Prince
Rankless by CCL
2026